Novel immunological approaches in the treatment of Atopic eczema

Benedetta Belloni, Christian Andres, Markus Ollert, Johannes Ring, Martin Mempel*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

28 Citations (Scopus)


Purpose of review Atopic eczema is a common inflammatory skin disease showing chronically relapsing eczema and high association with elevated serum IgE levels. A subgroup of atopic eczema patients requires systemic immunomodulatory treatment for long time periods. However, beyond cyclosporine A and azathioprine, only limited consent exists on systemic treatment options. Recent findings Timely published systemic treatment modalities include studies on efalizumab (anti-CD11a antibody), infliximab, adalimumab, and etanercept (anti-TNF-α treatment), omalizumab (an anti-lgE antibody), rituximab (an anti-CD20 antibody), specific immunotherapy, leflunomide, and leukotriene receptor antagonists with varying clinical results and with particular safety profiles. Summary Although there is not yet a treatment modality reaching clinical efficacy of cyclosporine A as gold standard of systemic therapy, limitation in its application duration as in its side effect profile as well as the search for alternatives has set a focus on the new alternatives of which especially B-cell-directed therapies might be promising candidates.

Original languageEnglish
Pages (from-to)423-427
Number of pages5
JournalCurrent Opinion in Allergy and Clinical Immunology
Issue number5
Publication statusPublished - Oct 2008
Externally publishedYes


  • Atopic eczema
  • Efalizumab
  • Leflunomide
  • Leukotriene receptor antagonists
  • Omalizumab
  • Rituximab
  • Sublingual immunotherapy
  • Tumor necrosis factor-α antagonists


Dive into the research topics of 'Novel immunological approaches in the treatment of Atopic eczema'. Together they form a unique fingerprint.

Cite this